ReviewCurrent atherosclerosis reports2012
The role of non-HDL cholesterol in risk stratification for coronary artery disease.
Review in Current atherosclerosis reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 64 citations in OpenAlex.
- Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.Diabetes care · 2023Trial
- Effects of aerobic training with and without weight loss on insulin sensitivity and lipids.PloS one · 2018Trial
- Predictors of improvement in cardiometabolic risk factors with weight loss in women.Journal of the American Heart Association · 2013Trial
- Article
- Comparative Predictive Value of Three Visceral Adiposity Indices for Cardiovascular Disease: A 17.5-Year Korean Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Preheparin Serum Lipoprotein Lipase Mass as a Coronary Risk Factor in Patients With Chronic Kidney Disease.Cardiology research · 2026Article
- Integrating Thyroid Function with Body Composition: The BRITSH Ratio and Cardiovascular Risk - A Pilot Study.Anatolian journal of cardiology · 2025Article
- Exploring the relationship between NHHR and the degree of coronary artery stenosis in patients with acute coronary syndromes.BMC cardiovascular disorders · 2025Article
- Cluster-Based Analysis of Lipid Profiles and Inflammation in Association With Cardiovascular Disease Incidence and Mortality: A 17.5-Year Longitudinal Study.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- New discoveries in the field of metabolism by applying single-cell and spatial omics.Journal of pharmaceutical analysis · 2023Review
- Fixed dose combination drugs for cardiovascular disease in a prolonged humanitarian crisis in Lebanon: an implementation study.BMJ open · 2023Article
- Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia.International journal of molecular sciences · 2022Review
- Emerging roles of sortilin in affecting the metabolism of glucose and lipid profiles.Bosnian journal of basic medical sciences · 2022Review
- Association between Heavy Metal Exposure and Dyslipidemia among Korean Adults: From the Korean National Environmental Health Survey, 2015-2017.International journal of environmental research and public health · 2022Article
- ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.Current atherosclerosis reports · 2021Review
- To fast or not to fast: Lipid measurement and cardiovascular disease risk estimation in rural sub-Saharan Africa.Journal of global health · 2020Article
- Replication and fine-mapping of genetic predictors of lipid traits in African-Americans.Journal of human genetics · 2017Article
- Non-high-density lipoprotein cholesterol predicts nonfatal recurrent myocardial infarction in patients with ST segment elevation myocardial infarction.Lipids in health and disease · 2017Article
- ASGR1 - a new target for lowering non-HDL cholesterol.Global cardiology science & practice · 2016Article
- Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.The New England journal of medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite aggressive lipid-lowering therapy, patients continue to be at significant risk of coronary heart disease (CHD). Assessment of non-high-density lipoprotein cholesterol (non-HDL-C) provides a measure of cholesterol contained in all atherogenic particles. In the third Adult Treatment Panel (ATP III) guidelines of the US National Cholesterol Education Program, non-HDL-C was introduced as a secondary target of therapy in persons with triglycerides ≥200 mg/dL. A recent meta-analysis of the relationship between non-HDL-C reduction and CHD risk showed non-HDL-C as an important target of therapy for CHD prevention. Most lipid-modifying drugs used as monotherapy have a 1:1 relationship between percent non-HDL-C lowering and percent CHD reduction. In the EPIC-Norfolk prospective population study, 21,448 participants without diabetes or CHD between 45 and 79 years of age were followed for 11.0 years. Participants with high non-HDL-C levels were at increased CHD risk independently of their LDL-C levels. Also, compared to apolipoprotein B, non-HDL-C appears to be a better choice given the fact that no additional tests or costs are needed and established cut points are already available. Future guidelines should emphasize the importance of non-HDL-C for guiding cardiovascular prevention strategies with an increased need to have non-HDL-C reported on routine lipid panels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.